Dicot Pharma has initiated Part I of its Phase IIb study of LIB-01 in erectile dysfunction (ED) with the first patient screened at a US centre, marking an important step towards dose optimisation and broader clinical validation ahead of Phase III. Part I will establish the highest dose for evaluation in Part II, with completion expected in Q127. The overall adaptive study will enrol at least 200 patients across the US and Europe, assessing three dose levels under a repeated monthly dosing regimen. We note that while the prior Phase IIa demonstrated encouraging durability of effect, lasting up to eight weeks, statistically significant placebo-adjusted improvements were primarily observed in patients with moderate ED. Phase IIb will therefore be critical in establishing reproducible efficacy across a broader patient population and validating LIB-01’s differentiation from conventional on-demand treatments such as PDE5 inhibitors. With the study fully funded by the SEK231.3m raise in June 2026, attention now shifts to Part I completion and subsequent progression into the efficacy-focused Part II, potentially strengthening Phase III readiness and partnering appeal.
LÄS MER